![Prof. Dr. Fatma Paksoy Turkoz, [object Object]](/_next/image?url=https%3A%2F%2Fd3fzwscyjtgllx.cloudfront.net%2Fuploads%2Fimages%2Fimg_637b12e61fe9f1669010150.png&w=3840&q=60)
Prof. Dr. Fatma Paksoy Turkoz
Medical Oncologist
Consults at:
4.0
Surgeries
N/A
Experience
N/A years
FAQs
Prof. Dr. Fatma Paksoy Turkoz specializes in Medical Oncology.
Medical Oncologist
Consults at:
4.0
Specialty: Medical Oncology
Special Interests:
Stomach cancer
Breast cancer
Lung cancer
Medical Education at Istanbul University's Cerrahpaşa Faculty of Medicine
Işli Etfal Training and Research Hospital - Internal Medicine, T.C. Ministry of Health (Major) Dr. A. Yurtaslan of the T.C. Ministry of Health Medical Oncology at Ankara Oncology Training and Research Hospital (Minor)
Professional affiliations
Association for Turkish Medical Oncology Association for Anatolian Medical Oncology
Association for Breast Diseases in Ankara Association for Lung Cancer in Turkey International Society of Medical Oncology
Medical Association of Turkey
Awards
BEST STUDY FIRST PRIZES FOR FIRST ARE KNOWN Do Breast Cancer Risk Factors Affect Luminal, HER-2 Positive, and Triple Negative Subtype Development in the Same Way? F.Paksoy Türköz, M.Solak, "Keskin," "Petekkaya," F. Sarc, and "K." Altoona 2012, Antalya, 4th Medical Oncology Congress. Award for Best Oral Presentation at the Second Prof. Dr. Mustafa Samur Paper Awards Advanced Stage Gastric Cancer Docetaxel 60 Cisplatin 60 and 46 Hours Infusional 5-FU (Modified DCF) Application (ATOD Study). S.Alc, S.Büyükberber, M.Zkan, U.Demirci, N.Alkş, M.Altnbaş, M.Spotkli, V.Berk, F.Paksoy, and U.Coşkun are some of the names in the group. 2009's 6th National Medical Oncology Congress was held in Antalya. Third-best-study-second-place award QTc Duration in Metabolic Syndrome Patients F. Paksoy, L. N. Adn, C. Bes, M. Solak, and F. Borlu.
2006's 8th National Internal Medicine Congress was held in Antalya.
Projects that she worked on 1. A global, multicenter, randomised study (co-investigator) Neratinib After Trastuzumab in Women With Early-Stage HER-2/Neu Overexpressed/ Amplified Breast Cancer: A Randomized Double-Blind Placebo-Controlled Trial
